Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

644P - Preliminary results of GQ1005 in metastatic HER2-low expressing breast cancer and HER2 positive gastric cancer

Date

14 Sep 2024

Session

Poster session 01

Topics

Tumour Site

Breast Cancer;  Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Ting Deng

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

T. Deng1, Y. Sun2, B. Wang3, J. Zhang4, C. Zhou5, J. Wang6, H. Yang7, B. Yang8, J. Wei9, R. Lin10, J. Liu11, E. Li12, Y. Ji13, L. Wang14, X. Wang15, Z. Li16, Y. Yang1

Author affiliations

  • 1 Medical Oncology Department, Tianjin Medical University Cancer Institute & Hospital, 300060 - Tianjin/CN
  • 2 Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, 250117 - Jinan/CN
  • 3 Breast And Urologic Medical Oncology Dept., Fudan University Cancer, 200032 - Shanghai/CN
  • 4 Department Of Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 5 Medical Oncology Department, Shanghai East/Oriental Hospital Affiliated to Tongji University - Headquarters/Northern Division, 200120 - Shanghai/CN
  • 6 Department Ii Of Breast, Tumor Hospital in Linyi City, 276000 - Linyi/CN
  • 7 Department Of Breast And Thyroid Surgery, Suining Central Hospital, 629000 - Suining/CN
  • 8 Department Of Oncology, Chinese PLA General Hospital (301 Military Hospital), 100853 - Beijing/CN
  • 9 Oncology Department, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 210008 - Nanjing/CN
  • 10 Oncology Department, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 11 Department Of Oncology, Shengjing Hospital of China Medical University, 110055 - Shenyang/CN
  • 12 Medical Oncology Department, The First Affiliated Hospital of Xi’an Jiaotong University, 710061 - Xi'an/CN
  • 13 Department Of Oncology, The First Affiliated Hospital of Xinxiang Medical University, 453110 - Xinxiang/CN
  • 14 Thoracic Radiotherapy Dept., Shandong Cancer Hospital and Institute, 250117 - Jinan/CN
  • 15 Gynecologic Oncology Department, Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, 310016 - Hangzhou/CN
  • 16 Department Of Oncology, Harbin Medical University Cancer Hospital, 150000 - Harbin/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 644P

Background

GQ1005 is an innovative anti-HER2 antibody-drug conjugate (ADC) processed through a novel, integrated and stable enzyme conjugation links DXd to engineered trastuzumab, the drug-to-antibody ratio is 4.

Methods

In the FIH phase 1a/1b study, patients(pts) of HER2 expressing/mutated metastatic solid tumors progressed from the standard of care were included. Dose escalation was ranged from 2 to 9.6 mg/kg (2, 4, 6, 7.2, 8.4 and 9.6 mg/kg). Safety and efficacy were investigated Q3W as well as in the expansion stage.

Results

By April 19th, 2024, 165 pts were enrolled (the median age 55 [range 34-74] with the median line of prior therapy 3 [range 1-11]), including 55 HER2 positive BC, 35 HER2 low BC, 43 HER2 exon19/20 mutant lung cancer and 26 HER2 expressing (IHC2+/3+) gastric cancer pts. The median exposure time of GQ1005 was 12.0 weeks (3.0-63.7). No DLT was observed up to the highest dose. Only 28 and 14 of the 153 safety evaluable pts had ≥ G3 TRAE (18.3%) and the drug related SAE (9.2%), respectively. TRAEs (>20%) are shown in the table. Tumor response was observed from 4 mg/kg. In 29 efficacy evaluable HER2 low BC pts with the median prior therapies of 3, ORR was 27.6% and DCR was 69.0%, mPFS was 10.4m (2.3-NA) and mDOR was 11.9m (6.1-NA). Of 15 efficacy evaluable HER2 positive GC pts, 14 received trastuzumab, 6 received other HER2 ADCs, and 4 received HER2 TKIs. ORR, DCR and 6-mo PFS rate were 33.3%, 80.0%, and 70.0%, respectively. AE profile of both cohorts was consistent with whole population. Only 1 ILD occurred in each cohort. Table: 644P

TRAEs (>20%) All Grade n=153(%) ≥ G3 n=153 (%)
Nausea 64 (41.8) 0
AST increased 63 (41.2) 2 (1.3)
Anemia 52 (34.0) 6 (3.9)
ALT increased 47 (30.7) 1 (0.7)
Leukopenia 42 (27.5) 3 (2.0)
Thrombocytopenia 39 (25.5) 2 (1.3)
Decreased appetite 36 (23.5) 1 (0.7)
Neutropenia 35 (22.9) 1 (0.7)
Vomiting 32 (20.9) 1 (0.7)

Conclusions

GQ1005 demonstrates excellent safety profile and encouraging antitumor activity in HER2 expressing tumors, including heavily treated HER2 low BC and HER2 positive GC. Given the wider therapeutic window and the safer profile of GQ1005, a superior survival benefit could be expected from the patients treated with GQ1005. (Sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd.).

Clinical trial identification

NCT06154343.

Editorial acknowledgement

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Legal entity responsible for the study

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Funding

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Disclosure

C. Zhou: Financial Interests, Personal, Advisory role, Consulting fees: Innovent Biologics, Qilu, Hengrui, TopAlliance Biosciences Inc.; Financial Interests, Personal, Other, Payment or honoraria from: Eli Lilly China, Sanofi, Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Qilu, Hengrui, Innovent Biologics, Alice, C-Stone, Luye Pharma, TopAlliance Biosciences Inc., Amoy Diagnostics, AnHeart. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.